In ovarian and breast cancer, promoter methylation of BRCA1 or RAD51C is a promising biomarker for PARP inhibitor response, as high levels lead to homologous recombination deficiency (HRD). Here, RAD51C is linked to hypoparathyroidism-retardation-dysmorphism syndrome.